Driving Innovation: ViiV Healthcare's Long‑Acting Pipeline
Assets in development target multiple stages of the HIV life cycle with expanded dosing options
1
Binding and Fusion1
VH3810109 (N6LS)
Class: bNAb
Phase: IIb
2
Nuclear Entry & Uncoating1
VH4011499
Class: Capsid Inhibitor
Phase: IIa
3
Integration1
Cabotegravir – ULA (Tx/PrEP)
Class: INSTI
Phase: Ia/IIb
VH45241843
Class: INSTI
Phase: IIa
VH4367310
Class: INSTI
Phase: Ia (H2, 2026)4
4
Assembly and Budding1
VH4011499
Class: Capsid Inhibitor
Phase: IIa
- GSK. ViiV Healthcare meet the management: Getting ahead of HIV together – 2023. Available at: https://www.gsk.com. Accessed April 2025
- NCT06652958. Available at: https://clinicaltrials.gov. Accessed April 2025.
- NCT06214052. Available at: https://clinicaltrials.gov. Accessed April 2025
- Baker M, et al.